Arbutus to participate in two upcoming investor conferences

Warminster, pa., sept. 03, 2024 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis b virus (chbv) infection, today announced that the arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in new york:
ABUS Ratings Summary
ABUS Quant Ranking